Marc Legris, MD
Internal Medicine · Norwalk, CTNPI 1114935723
Payments from drug & device makers
Across 230 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$562
- Novo Nordisk$416
- GSK$405
- Axsome Therapeutics, Inc.$331
- Otsuka America Pharmaceutical, Inc.$322
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$293
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,524100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $562 |
| Novo Nordisk | 19 | $416 |
| GSK | 21 | $405 |
| Axsome Therapeutics, Inc. | 14 | $331 |
| Otsuka America Pharmaceutical, Inc. | 18 | $322 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $293 |
| Exact Sciences | 12 | $249 |
| Lundbeck LLC | 19 | $243 |
| Merck | 12 | $242 |
| ANI Pharmaceuticals, Inc. | 9 | $213 |
| Amgen | 7 | $154 |
| Neurocrine Biosciences, Inc. | 4 | $110 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $107 |
| Lilly USA, LLC | 5 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| AbbVie | 4 | $88 |
| Phathom Pharmaceuticals, Inc. | 5 | $68 |
| Bayer | 3 | $65 |
| Ardelyx, Inc. | 3 | $61 |
| Viatris Specialty LLC | 3 | $53 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Harmony Biosciences LLC | 2 | $36 |
| CSL Behring | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Corcept Therapeutics | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Lucid Diagnostics Inc. | 1 | $23 |
| Pfizer | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$4,531 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 14 | $25,238 |
| FarxigaDapagliflozin Propanediol | 16 | $19,620 |
| OzempicSemaglutide | 15 | $14,741 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,845 |
| JardianceEmpagliflozin | 12 | $7,405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $1,439 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,240 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $1,046 |
| Gabapentin | 44 | $920 |
| Atorvastatin Calcium | 47 | $747 |
| Clonazepam | 34 | $686 |
| Fluticasone Propionate | 34 | $632 |
| Rosuvastatin Calcium | 54 | $559 |
| Bupropion Hcl SrBupropion Hcl | 17 | $465 |
| Metformin Hcl | 44 | $460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $19 | $25,23814 claims |
| AstraZenecaFarxiga | $562 | $19,62016 claims |
| Novo NordiskOzempic | $416 | $14,74115 claims |
| GSKTrelegy Ellipta | $405 | $12,84520 claims |
| Boehringer IngelheimJardiance | $15 | $7,40512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Norwalk
- Gary BlickNorwalk$717K
- Anthony BreemoNorwalk$36K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.